AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01536639 — intervention group
Intervention type: DRUG
Intervention: biphasic insulin aspart 30
Description: Administered by subcutaneous injection. The physician determined the starting dose and frequency, as well as later changes to either dose or frequency, if any
Study NCT00514267 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM 155
Description: IV
Study NCT00514267 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: IV
Study NCT00514267 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Oral
Study NCT03668613 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: secukinumab low dose
Description: dose depends on the weight group
Study NCT03668613 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: secukinumab high dose
Description: dose depends on the weight group
Study NCT00061568 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral blood hematopoietic progenitor cell (PBPC) transplant
Description: Peripheral blood hematopoietic progenitor cell (PBPC) transplant
Study NCT02355132 — intervention group
Intervention type: OTHER
Intervention: Insurance Intervention
Description: Random selection to apply for Medicaid coverage through Oregon Experiment drawings held between March and October 2008
Study NCT02188368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: POM
Study NCT02188368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Steroids
Study NCT02188368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLD
Study NCT02188368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CFZ
Study NCT02188368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BTZ
Study NCT02188368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CLA
Study NCT02188368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CY
Study NCT01713868 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Safe Sleep Nursery Education
Description: Nursery-based program for safe sleep
Study NCT01713868 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Breastfeeding Nursery Education
Description: Nursery-based program to promote breastfeeding
Study NCT01713868 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Breastfeeding Mobile Health Messaging
Description: Mobile messaging to provide multiple short culturally competent videos to promote breastfeeding delivered via email.
Study NCT01713868 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Safe Sleep Mobile Health Messaging
Description: Mobile messaging to provide multiple short culturally competent videos to promote safe sleep practices delivered via email.
Study NCT02020668 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Study NCT02020668 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Wait list control
Study NCT03018392 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stryker Tritanium Spinal System
Description: open transforaminal lumbar interbody fusion (TLIF) utilizing the Stryker Tritanium cages with pedicle screw fixation according to instructions for use and package labeling for on-label indications
Study NCT01558700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: Duloxetine capsule 30mg once a day for one week, then 60mg once a day for 15 weeks, then 30mg once a day for one week.
Study NCT01558700 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar pill
Description: Matching capsule given once a day for a total of 17 weeks.
Study NCT01234129 — intervention group
Intervention type: DRUG
Intervention: zoledronic acid
Description: zoledronic acid, 4 mg,standard dose,at monthly interval, by 2 years
Study NCT02085564 — intervention group
Intervention type: PROCEDURE
Intervention: Peritoneal washing cytology
Description: The methode is describes in the detailed study description
Study NCT03152318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rQNestin
Description: rQNestin is an oncolytic viral vector. It is administered via intratumoral injection during biopsy surgery.
Study NCT03152318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide is an immunomodulating agent. It is administered intravenously in a single dose 2 days (+/- 6 hrs) before surgery.
Study NCT03152318 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stereotactic biopsy
Description: In both arms, subjects will undergo standard of care stereotactic biopsy in the intraoperative MRI operating room. The stereotactic needle will be placed stereotactically into the tumor bed using intraoperative MRI guidance to collect the biopsy, and again to administer the rQNestin oncolytic virus.
Study NCT02659215 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyalofast
Description: Implantation of Hyalofast scaffold with autologous bone marrow aspirate concentrate via arthroscopy/mini-arthrotomy.
Study NCT02659215 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Microfracture
Description: Microfracture is a well-established arthroscopic surgical technique for cartilage repair which involves several systematic steps, including debridement to a stable cartilage margin, careful removal of the calcified cartilage layer, and homogeneous placement of microfracture penetrations within the cartilage defect, with resultant complete defect fill by a well-anchored clot
Study NCT04015219 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Self retained cryopreserved amniotic membrane
Description: PROKERA SLIM
Study NCT04015219 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: lifitegrast ophthalmic solution
Description: Xiidra® (5% lifitegrast ophthalmic solution, Shire, Lexington, MA)
Study NCT04015219 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: lifitegrast ophthalmic solution
Description: Xiidra® (5% lifitegrast ophthalmic solution, Shire, Lexington, MA)
Study NCT00061568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: Alemtuzumab
Study NCT00061568 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral blood hematopoietic progenitor cell Apheresis
Description: Donor-Peripheral blood hematopoietic progenitor cell (PBPC) apheresis
Study NCT00061568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Sirolimus
Study NCT04024527 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole
Description: Proton pump inhibitor
Study NCT04024527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: Proton pump inhibitor
Study NCT04024527 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: Antibiotic for H. pylori eradication
Study NCT04024527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: Antibiotic for H. pylori eradication
Study NCT04024527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: Antibiotic for H. pylori eradication
Study NCT01734421 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control group
Description: 6-month implementation of recommendations of a Clinical Practice Guideline smoking cessation
Study NCT01734421 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cell phone Aplication for Smarth Phone
Study NCT01042379 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Therapy
Description: Paclitaxel: 80 mg/m2 IV during the 12 weekly treatment cycles post randomization; Doxorubicin: 60 mg/m2 IV after completion of the 12 weekly treatment cycles and prior to surgery for weeks 13-16; Cyclophosphamide: 600 mg/m2 IV after completion of the 12 weekly treatment cycles and prior to surgery for weeks 13-16
Study NCT01042379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 386 with or without Trastuzumab
Description: Arm is closed.
Study NCT01042379 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: AMG 479 (Ganitumab) plus Metformin
Description: Arm is closed.
Study NCT01042379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-2206 with or without Trastuzumab
Description: Arm is closed.
Study NCT01042379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 386 and Trastuzumab
Description: Arm is closed.
Study NCT01042379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T-DM1 and Pertuzumab
Description: Arm is closed.
Study NCT01042379 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pertuzumab and Trastuzumab
Description: Pertuzumab: 840 mg IV (loading dose) week 1 and 420 mg every 3 weeks (weeks 4, 7, 10) post-randomization; Trastuzumab: 4 mg/kg (loading dose) week 1 and 2 mg/kg weekly (weeks 2-12) post-randomization
Study NCT01042379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganetespib
Description: Arm is closed.
Study NCT01042379 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: ABT-888
Description: Arm is closed.
Study NCT01042379 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Neratinib
Description: Arm is closed.
Study NCT01042379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLX3397
Description: Arm is closed.
Study NCT01042379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab - 4 cycle
Description: Arm is closed.
Study NCT01042379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib plus Irinotecan
Description: Arm is closed.
Study NCT01042379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patritumab and Trastuzumab
Description: Arm is closed.
Study NCT00763659 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lutein/ Zeaxanthin + Omega-3-FA
Description: 20mg Lutein, 2mg Zeaxanthin, 510 mg Omega-3-FA; daily supplementation about one year
Study NCT00763659 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lutein/ Zeaxanthin + Omega-3-FA
Description: 10mg Lutein, 1mg Zeaxanthin, 255 mg Omega-3-FA; daily supplementation about one year
Study NCT00763659 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0 mg Lutein, Zeaxanthin, Omega-3-FA
Study NCT03595111 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: myocardial biopsy
Description: Myocardial cell edema either focal or diffuse was detected in histopathological examination
Study NCT00646204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine
Description: 10 mg bid
Study NCT00646204 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 2 tabs bid
Study NCT03394872 — intervention group
Intervention type: PROCEDURE
Intervention: Drainage of the pleural effusion
Study NCT01042379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab - 8 cycle
Description: Arm is closed.
Study NCT02348242 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aqueous Gel
Description: 1 drop of Dexpanthenol® 0.2% aqueous gel in the eye every 6 hours
Study NCT02348242 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Eyelid Occlusion Dressing
Description: Eyelid occlusion using pro-ophta® eyelid occlusion dressing, dressing to be verified every 6 hours and replaced daily
Study NCT02348242 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Artificial Tears
Description: 1 drop of Phylarm® artificial tears in the eye every 6 hours
Study NCT03490266 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robotic Repair
Description: The surgeon will be utilizing a robotic system to repair the hernia.
Study NCT03490266 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic Repair
Description: The surgeon will be repairing the hernia laparoscopically.
Study NCT02880566 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Scalp block
Description: Full scalp block
Study NCT02880566 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Scalp block
Description: Full scalp block
Study NCT01042379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGN-LIV1A
Description: Arm is closed. SGN-LIV1A: 2.5 mg/kg IV cycles 1,4,7,10 Doxorubicin + Cyclophosphamide: Cycles 13-16
Study NCT01042379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab plus Olaparib
Description: Arm is closed.
Study NCT01042379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SD-101 + Pembrolizumab
Description: Arm is closed. SD-101: IT injection 2 mg/ml (1 ml for T2 tumors, 2 ml for >T3 tumors) weekly x 4, then every 3 weeks x 2 cycles 1,2,3,4,7,10 Pembrolizumab: 200mg IV cycles 1,4,7,10 Paclitaxel: 80 mg/m2 IV cycles 1-12 Doxorubicin + Cyclophosphamide: Cycles 13-16; Doxorubicin: 60 mg/m2 IV Every 2 or 3 weeks for 4 cycles; Cyclophosphamide: 600 mg/m2 IV Every 2 or 3 weeks for 4 cycles
Study NCT01518075 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Spontaneous Breathing
Description: Evaluation of breathing - swallowing interaction without non invasive mechanical ventilation. Patient breath spontaneously.~Measurements of respiratory and swallowing parameters were monitored using respiratory inductive plethysmography. Swallowing was monitored noninvasively. Two bolus sizes were used, (5, 10 ml), in random order. Five sets of two boluses were studied, taking care not to use the same bolus size twice consecutively. The study participants were blinded to bolus size.
Study NCT01518075 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non Invasive Mechanical Ventilation
Description: Evaluation of breathing - swallowing interaction with non invasive mechanical ventilation. Patient breath under non invasive mechanical ventilation. Measurements of respiratory and swallowing parameters were monitored using respiratory inductive plethysmography. Swallowing was monitored noninvasively. Two bolus sizes were used, (5, 10 ml), in random order. Five sets of two boluses were studied, taking care not to use the same bolus size twice consecutively. The study participants were blinded to bolus size.
Study NCT04035785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kangfu Anti-inflammatory Suppository
Description: To evaluate the short-term and long-term efficacy of traditional Chinese medicine of Kangfu anti-inflammatory suppository in reducing the use of antibiotics,reducing the risk of clinical use of drugs.
Study NCT04035785 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Kangfu Anti-inflammatory Suppository
Description: To evaluate the short-term and long-term efficacy of traditional Chinese medicine of Kangfu anti-inflammatory suppository in reducing the use of antibiotics,reducing the risk of clinical use of drugs.
Study NCT02611167 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic bone marrow-derived MSCs (1 x 10 6 MSC/kg)
Description: Bone marrow-derived allogeneic MSCs will be delivered intravenously in escalating doses of 1 x 10 6 MSC/kg, 3 x 10 6 MSC/kg, 6 x 10 6 MSC/kg, or 10 x 10 6 MSC/kg of body weight to a population of patients with idiopathic Parkinson's disease (iPD).
Study NCT02611167 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic bone marrow-derived MSCs (3 x 10 6 MSC/kg)
Description: Bone marrow-derived allogeneic MSCs will be delivered intravenously in escalating doses of 1 x 10 6 MSC/kg, 3 x 10 6 MSC/kg, 6 x 10 6 MSC/kg, or 10 x 10 6 MSC/kg of body weight to a population of patients with idiopathic Parkinson's disease (iPD).
Study NCT02611167 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic bone marrow-derived MSCs (6 x 10 6 MSC/kg)
Description: Bone marrow-derived allogeneic MSCs will be delivered intravenously in escalating doses of 1 x 10 6 MSC/kg, 3 x 10 6 MSC/kg, 6 x 10 6 MSC/kg, or 10 x 10 6 MSC/kg of body weight to a population of patients with idiopathic Parkinson's disease (iPD).
Study NCT02611167 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic bone marrow-derived MSCs (10 x 10 6 MSC/kg)
Description: Bone marrow-derived allogeneic MSCs will be delivered intravenously in escalating doses of 1 x 10 6 MSC/kg, 3 x 10 6 MSC/kg, 6 x 10 6 MSC/kg, or 10 x 10 6 MSC/kg of body weight to a population of patients with idiopathic Parkinson's disease (iPD).
Study NCT01560624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treprostinil Diolamine
Description: Active
Study NCT01560624 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04341480 — intervention group
Intervention type: DRUG
Intervention: Chemotherapy
Description: Routine chemotherapy for individual tumor type.
Study NCT02063997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arhalofenate 600 mg
Description: Arhalofenate 600 mg tablets once daily for 12 weeks
Study NCT02063997 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Allopurinol 300 mg
Description: Allopurinol 300 mg tablets once daily for 12 weeks
Study NCT02063997 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine 0.6 mg
Description: Colchicine 0.6 mg over-encapsulated tablets once daily for 12 weeks
Study NCT02063997 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets once daily for 12 weeks
Study NCT02063997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arhalofenate 800 mg
Description: Arhalofenate 800 mg tablets once daily for 12 weeks
Study NCT03446703 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SCIT
Description: SCIT is a 18 weekly sessions lasting 45-60 minutes per session. The group will include 8-12 patients, with 2 therapists. The content of the sessions is based on the Spanish translation of the original SCIT (Social Cognition and Interaction Training) instruction manual (Combs, Adams, et al., 2007); (G. Lahera et al., 2013). The manual of the program developed for the improvement of emotional perception skills, attributional style and theory of mind in people with schizophrenia.
Study NCT03446703 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TAR
Description: TAR is a 12-session training on facial affect recognition over a period of 6 weeks. Treatment includes one therapist (psychiatrist or clinical psychologist) and 2 patients. It involves neuropsychological strategies, such as restitution and compensation, as well as principles of errorless learning, direct positive reinforcement, verbalization and self-instruction (Frommann et al., 2003; Wölwer et al., 2005).
Study NCT01797536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elbasvir
Study NCT01042379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tucatinib plus trastuzumab and pertuzumab
Description: Arm is closed. Tucatinib: 300 mg PO BID 12 weeks CLOSED Tucatinib: 250 mg PO BID 12 weeks CLOSED Tucatinib adaptive: 150mg BID days 1-28, 250mg BID days 29-84 Trastuzumab: 4 mg/kg IV (loading dose) cycle 1; 2 mg/kg (thereafter) cycles 2-12 Pertuzumab: 840 mg IV (loading dose) cycle 1; 420 mg (thereafter) cycles 4, 7 and 10 Paclitaxel: 80 mg/m2 IV cycles 1-12 Doxorubicin + Cyclophosphamide: Cycles 13-16; Doxorubicin: 60 mg/m2 IV Every 2 or 3 weeks for 4 cycles; Cyclophosphamide: 600 mg/m2 IV Every 2 or 3 weeks for 4 cycles
Study NCT01042379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Cemiplimab: 350 mg q3w X 12 weeks IV cycles 1,4,7,10 Paclitaxel: 80 mg/m2 IV cycles 1-12 Doxorubicin + Cyclophosphamide: Cycles 13-16; Doxorubicin: 60 mg/m2 IV Every 2 or 3 weeks for 4 cycles; Cyclophosphamide: 600 mg/m2 IV Every 2 or 3 weeks for 4 cycles
Study NCT01042379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab plus REGN3767
Description: Cemiplimab: 350 mg q3w X 12 weeks IV cycles 1,4,7,10 REGN 3767: 1600 mg q3W X 12 weeks IV cycles 1,4,7,10 Paclitaxel: 80 mg/m2 IV cycles 1-12 Doxorubicin + Cyclophosphamide: Cycles 13-16; Doxorubicin: 60 mg/m2 IV Every 2 or 3 weeks for 4 cycles; Cyclophosphamide: 600 mg/m2 IV Every 2 or 3 weeks for 4 cycles
Study NCT03447171 — intervention group
Intervention type: DEVICE
Intervention: App Vision Screening
Description: Using GoCheck Kids App Vision Screening to detect Amblyopia Risk Factors
Study NCT00797992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Injection
Description: Intravitreal injection of 1.25 mg bevacizumab
Study NCT00668681 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EndoRefix
Study NCT02994342 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal gel, Medical Device Class 2A
Description: Application twice a day of vaginal gel for 56 consecutive days
Study NCT01558882 — intervention group
Intervention type: DEVICE
Intervention: Essure
Description: Essure devices are deployed according to manufacturer's instructions for tubal sterilization.